back to optometry, because we now have the injectables [Syfovre and Izervay, intravitreal injections recently approved for dry AMD] as well as MacuMira,” Dr Sharma said.

PATIENT PROFILE For Dr Luzhansky and Dr Sharma, one of the major barriers to treatment is the cost, as MacuMira procedures are not yet subsidised or rebated in any way.

“It’s a very good adjuvant to have because there are lots of patients who have nothing else that we can offer. This is something that is non-invasive, it’s safe, and so far, on the the limited number of people that we’ve seen, it’s been very well tolerated and they have had improvements,” Dr Luzhansky said.

“Almost everyone has had some improvement in their acuity, in their clarity, in their contrast sensitivity... but I think the limiting factor for the majority of the patients will be cost. If it was free or if it was subsidised, I believe it would become very popular,” she said.

* For further information including full patient profile and contraindictions, contact ParagonCare: (AUS) 1800 225 307.

Reference 1. Parkinson KM, Sayre EC, Tobe SW. Evaluation of visual acuity in dry AMD patients after microcurrent electrical stimulation. Int J Retina Vitreous. 2023 Jun 18;9(1):36. doi: 10.1186/s40942-023-00471-y.

48 Pirrama Road, Darling Island, Pyrmont